Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography
暂无分享,去创建一个
Jeih-San Liow | Cheryl L. Morse | Robert B. Innis | Victor W. Pike | Johannes T. Tauscher | Christer Halldin | Nicholas Seneca | Jussi Hirvonen | Christian C. Felder | Garth E. Terry | John M. Schaus | Lee Phebus | J. Hirvonen | C. Halldin | J. Liow | V. Pike | R. Innis | N. Seneca | C. Felder | J. Tauscher | L. Phebus | C. Morse | J. Schaus
[1] P. Pacher,et al. CB1 cannabinoid receptor inhibition: promising approach for heart failure? , 2008, Congestive heart failure.
[2] Jeih-San Liow,et al. Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand , 2009, NeuroImage.
[3] P. Caraceni,et al. The role of the endocannabinoid system in liver diseases. , 2009, Best practice & research. Clinical endocrinology & metabolism.
[4] S. Galiègue,et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.
[5] A. D. Roberts,et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] A. Makriyannis,et al. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? , 2009, Trends in pharmacological sciences.
[7] B. Schäfer,et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma , 2009, Molecular Cancer Therapeutics.
[8] Jeih-San Liow,et al. Radiation Dosimetry and Biodistribution in Monkey and Man of 11C-PBR28: A PET Radioligand to Image Inflammation , 2007, Journal of Nuclear Medicine.
[9] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] P. V. Ramzaev,et al. Limits for intakes of radionuclides by workers. , 1981, Annals of the ICRP.
[11] Jeih-San Liow,et al. Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands , 2010, Journal of Nuclear Medicine.
[12] W. S. Snyder,et al. Report of the task group on reference man , 1979, Annals of the ICRP.
[13] B. Basavarajappa. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. , 2007, Mini reviews in medicinal chemistry.
[14] C. Ledent,et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis , 2006, Nature Medicine.
[15] Koen Van Laere,et al. Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand 18F-MK-9470 in Healthy Subjects , 2008, Journal of Nuclear Medicine.
[16] David G. Cadena,et al. Limits for Intakes of Radionuclides by Workers. ICRP Publication 30, Part 3 , 1983 .
[17] Victor W. Pike,et al. Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. , 2008, Journal of medicinal chemistry.
[18] D. Mankoff,et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] D. Piomelli. The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.
[20] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[21] J. Liow,et al. Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] Lindsey L. Glickfeld,et al. Self-administering cannabinoids , 2005, Trends in Neurosciences.
[23] David A Lewis,et al. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. , 2008, Archives of general psychiatry.
[24] A. Sanyal,et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis , 2001, Nature Medicine.
[25] R. Mechoulam,et al. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. , 2008, European journal of pharmacology.
[26] M. Nagarkatti,et al. Activation through Cannabinoid Receptors 1 and 2 on Dendritic Cells Triggers NF-κB-Dependent Apoptosis: Novel Role for Endogenous and Exogenous Cannabinoids in Immunoregulation1 , 2004, The Journal of Immunology.